A distinct phenotypic change in gliomas at the time of magnetic resonance imaging detection: Laboratory investigation

Journal of Neurosurgery

Volumn 108, Issue 4, 2008, Pages 782-790

  Jang, Taichang ^a   Sathy, Binulal ^b   Hsu, Yi Hua ^b   Merchant, Milton ^a   Recht, Benjamin ^c   Chang, Chen ^b   Recht, Lawrence ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Ethylnitrosourea induced neurocarcinogenesis; Glioma; Magnetic resonance imaging; Nestin; Osteopontin

Indexed keywords

ETHYLNITROSOUREA; GLIAL FIBRILLARY ACIDIC PROTEIN; NESTIN; OSTEOPONTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; GLIOMA; HISTOCHEMISTRY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROGNOSIS; RAT; TUMOR GROWTH;

ALKYLATING AGENTS; ANIMALS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ETHYLNITROSOUREA; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOMA; INTERMEDIATE FILAMENT PROTEINS; MAGNETIC RESONANCE IMAGING; MALE; NERVE TISSUE PROTEINS; OSTEOPONTIN; PHENOTYPE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 41849124536     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/JNS/2008/108/4/0782     Document Type: Article

References (47)

1. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, et al: Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94:513-521, 2002
2. Alexandrov VA, Bespalov VG, Boone CW, Kelloff GJ, Malone WF: Study of postnatal effects of chemopreventive agents on offspring of ethylnitrosourea- induced transplacental carcinogenesis in rats. I. Influence of retinol acetate, a-tocopherol acetate, thiamine chloride, sodium selenite, and a-difluoromethylornithine. Cancer Lett 60:177-184, 1991
3. Alexandrov VA, Bespalov VG, Petrov AS, Troyan DN, Lidaks MY: Study of post-natal effect of chemopreventive agents on ethylnitrosourea-induced transplacental carcinogenesis in rats. III. Inhibitory action of indomethacin, voltaren, theophylline and ε-aminocaproic acid. Carcinogenesis 17:1935-1939, 1996
4. Alvarez L, Comendador MA, Sierra LM: Effect of nucleotide excision repair on ENU-induced mutation in female germ cells of Drosophila melanogaster. Environ Mol Mutagen 41:270-279, 2003
5. Beranek DT: Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat Res 231:11-30, 1990
6. Berenblum I, Shubik P: An experimental study of the initiating stage of carcinogenesis, and a re-examination of the somatic cell mutation of cancer. Br J Cancer 3:109-118, 1949
7. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, et al: Osteopontin expression and distribution in human carcinomas. Am J Pathol 145:610-623, 1994
8. Cappell MS: The pathophysiology, clinical presentation, and diagnosis of colon cancer and adenomatous polyps. Med Clin North Am 89:1-42, 2005
9. Ding Q, Stewart J, Prince CW, Chang PL, Trikha M, Han X, et al: Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. Cancer Res 62:5336-5343, 2002
10. Druckrey H: Genotypes and phenotypes of ten inbred strains of BD-rats. Arzneim-Forsch 21:1274-1278, 1971
11. Druckrey H, Ivankovic S, Preussmann R: Teratogenic and carcinogenic effects in the offspring after a single injection of ethylnitrosourea to pregnant rats. Nature 210:1378-1379, 1966
12. Druckrey H, Landschütz C, Ivankovic S: Transplacental induction of malignant tumors of the nervous system. II. Ethylnitrosourea in 10 genetically defined strains of rats. Z Krebsforsch 73:371-386, 1970
13. Gotoh M, Sakamoto M, Kanetaka K, Chuuma M, Hirohashi S: Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 52:19-24, 2002
14. Gunnersen JM, Spirkoska V, Smith PE, Danks RA, Tan SS: Growth and migration markers of rat C6 glioma cells identified by serial analysis of gene expression. Glia 32:146-154, 2000
15. Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner HH: Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int J Cancer 98:362-369, 2002
16. Imai Y, Feldman B, Schier AF, Talbot WS: Analysis of chromosomal rearrangements induced by postmeiotic mutagenesis with ethylnitrosourea in Zebrafish. Genetics 155:261-272, 2000
17. Ivankovic S, Druckrey H: Transplacentare Erzeugung maligner tumoren des Nervensystems. I. Äthyl-nitroso-harnstoff (ÄNH) an BD IX-ratten. Z Krebsforsch 71:320-360, 1968
18. Jang T, Litofsky NS, Smith TS, Ross A, Recht L: Aberrant nestin expression during ethylnitrosourea-(ENU)-induced neurocarcinogenesis. Neurobiol Dis 15:544-552, 2004
19. Jang T, Recht L: Experimental models for the study of CNS tumors, in Tatlisumak T, Fisher M (eds): Handbook of Experimental Neurology: Methods and Techniques in Animal Research. Cambridge: Cambridge University Press, 2006, pp 375-392
20. Jang T, Savarese T, Low HP, Kim S, Vogel H, Lapointe D, et al: Osteopontin (OPN) expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to Nethyl-N-nitrosourea (ENU). Am J Pathol 168:1676-1685, 2006
21. Kadkol SS, Lin AY, Barak V, Kalickman I, Leach L, Valyi-Nagy K, et al: Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Opthalmol Vis Sci 47: 802-806, 2006
22. Kao CL, Chiou SH, Ho DM, Chen Y, Liu R, Lo C, et al: Elevation of plasma and cerebrospinal fluid osteopontin levels in patients with atypical teratoid/rhabdoid tumor. Am J Clin Pathol 123: 297-304, 2005
23. Kish PE, Blaivas M, Strawderman M, Muraszko KM, Ross DA, Ross BD, et al: Magnetic resonance imaging of ethyl-nitrosourea-induced rat gliomas: a model for experimental therapeutics of low-grade gliomas. J Neurooncol 53:243-257, 2001
24. Kleihues P, Cavenee WK: Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press, 2000
25. Lantos PL, Cox DJ: The origin of experimental brain tumours: a sequential study. Experientia 32:1467-1468, 1976
26. Lantos PL, Pilkington GJ: The development of experimental brain tumors. A sequential light and electron microscope study of the subependymal plate. I. Early lesions (Abnormal cell clusters). Acta Neuropathol (Berl) 45:167-175, 1979
27. Nakajima M, Nakasu S, Morikawa S, Inubishi T: Estimation of volume doubling time and cell loss in an experimental rat glioma model in vivo. Acta Neurochir (Wien) 140:607-613, 1998
28. Nazzaro JM, Neuwelt EA: Surgical management of intracranial gliomas - Does radical resection improve outcome? J Neurosurg 73:331-344, 1990
29. Norden AD, Wen PY: Glioma therapy in adults. Neurologist 12: 279-292, 2006
30. Oates AJ, Barraclough R, Rudland PS: The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 17:1-15, 1997
31. Ohgaki H, Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol (Berl) 109:93-108, 2005
32. Pilkington GJ, Lantos PL: The development of experimental brain tumors. A sequential light and electron microscope study of the subependymal plate. II. Microtumors. Acta Neuropathol (Berl) 45:177-185, 1979
33. Rangaswami H, Bulbule A, Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16:79-87, 2006
34. Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BKA, et al: Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65:4051-4058, 2005
35. Rittling SR, O'Regan A, Berman JS: Osteopontin, a surprisingly flexible cytokine: functions revealed from knockout mice, in Fantuzzi G (ed): Contemporary Immunology: Cytokine Knockouts. Totowa, NJ: Humana Press, 2003, pp 379-393
36. Saitoh Y, Kuratsu J, Takeshima H, Yamamoto S, Ushio Y: Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest 72:55-63, 1995
37. Savarese TM, Jang T, Low HP, Salmonsen R, Litofsky NS, Matuasevic Z, et al: Isolation of immortalized, INK4a/ARF-deficient cells from the subventricular zone after in utero N-ethyl-N-nitrosourea exposure. J Neurosurg 102:98-108, 2005
38. Schiffer D, Giordana MT, Mauro A, Racagni G, Bruno F, Pezzotta S, et al: Experimental brain tumors by transplacental ENU. Multifactorial study of the latency period. Acta Neuropathol (Berl) 49:117-122, 1980
39. Schiffer D, Giordana MT, Pezzotta S, Lechner C, Paoletti P: Cerebral tumors induced by transplacental ENU: study of the different tumoral stages, particularly of early proliferations. Acta Neuropathol (Berl) 41:27-31, 1978
40. Shibuya T, Morimoto K: A review of the genotoxicity of N-ethyl-N-nitrosourea. Mutat Res 297:3-38, 1993
41. Singhal H, Bautista DA, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, et al: Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3:605-611, 1997
42. Trosko JE: Commentary. Is the concept of "tumor promotion" a useful paradigm? Mol Carcinog 30:131-137, 2001
43. Trosko JE, Chang CC: Mechanism of up-regulated gap junctional intercellular communication during chemoprevention and chemotherapy of cancer. Mutat Res 480-481:219-229, 2001
44. Tuck AB, Arsenault DM, O'Malley FP, Hota C, Ling MC, Wilson SM, et al: Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18:4237-4246, 1999
45. Wrensch M, Minn Y, Chew T, Bondy M, Berger M: Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-oncol 4:278-299, 2002
46. Wu Y, Denhardt DT, Rittling ST: Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer 83:156-163, 2000
47. Zook BC, Simmens SJ, Jones RV: Evaluation of ENU-induced gliomas in rats: nomenclature, immunohistochemistry, and malignancy. Toxicol Pathol 28:193-201, 2000